Transcenta Updates Efficacy Analysis of Osemitamab, Achieving 16.6 Months PFS
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 3 hour ago0mins
- Clinical Efficacy Update: At the ESMO Asia Congress, Transcenta presented updated efficacy analysis of osemitamab combined with nivolumab and CAPOX, revealing a median progression-free survival (PFS) of 16.6 months and an objective response rate (ORR) of 68% in 26 patients with CLDN18.2 expression ≥40%, indicating significant clinical benefits for advanced gastric cancer treatment.
- Safety Profile Consistency: The safety data from this analysis aligns with results presented at ASCO 2025, confirming that the combination of osemitamab with standard-of-care therapy is safe and well-tolerated, thereby enhancing its potential as a first-line treatment option.
- Impact of PD-L1 Expression: The study found that patients with higher CLDN18.2 expression exhibited better PFS outcomes across both PD-L1 CPS<1 and ≥1 subgroups, suggesting that the treatment benefit of osemitamab is consistent regardless of PD-L1 expression levels, potentially offering broader treatment options for advanced gastric cancer patients.
- Global Development Strategy: Transcenta is developing osemitamab globally as the second CLDN18.2 targeting monoclonal antibody, leveraging advanced bioprocessing technology to enhance its anti-tumor activity, showcasing the company's strong capabilities and market potential in antibody drug development.
06628.HK
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on 06628
Wall Street analysts forecast 06628 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 06628 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 2.570
Low
Averages
High
Current: 2.570
Low
Averages
High
No Data
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?